ArticleThe Journal of investigative dermatology2015

Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.

Nabanita Mukherjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.